Trikafta Recommended for 6-11 Year Olds
We are delighted to announce that, the Pharmaceutical Benefits Advisory Committee (PBAC), has today recommended Trikafta for children aged 6-11 years old who have at least one F508del mutation in the CFTR gene.
While this is positive news that we have been waiting for, the PBAC has not granted a facilitated (priority) pathway to its recommendation, as they did with patients 12+, which could delay access to the important medication.
The sooner Trikafta is available, the sooner the benefits can be realised, including reduction in infection, reduced hospitalisation, and the opportunity for a better quality of life We know how important this is for the community and we’ll continue advocating to get access as quickly as possible.
For the full release from Cystic Fibrosis Australia, click here.